Computational Analysis of <i>Plasmodium falciparum</i> Metabolism: Organizing Genomic Information to Facilitate Drug Discovery

Iwei Yeh, Theodor Hanekamp, Sophia Tsoka, Peter D. Karp, Russ B. Altman

Genome Research · 2004 · 224 citations · 43 references

DOIFull text

Open access

Concepts

TL;DR

The Plasmodium genome project seeks novel antimalarial targets, yet selecting optimal genes is difficult and systematic disruption is technically challenging, and a pathway/genome database integrates pathway and genomic data. The authors developed a computational approach to prioritize potential antimalarial targets. They built PlasmoCyc, enriched it with 956 GeneQuiz annotations, and applied a novel algorithm to identify 216 chokepoint enzymes, including all three clinically validated drug targets. The study found that 87.5 % of literature‑supported drug targets are chokepoint reactions, and that chokepoint enzymes provide a systematic means to identify metabolic drug targets.

Abstract

Identification of novel targets for the development of more effective antimalarial drugs and vaccines is a primary goal of the Plasmodium genome project. However, deciding which gene products are ideal drug/vaccine targets remains a difficult task. Currently, a systematic disruption of every single gene in Plasmodium is technically challenging. Hence, we have developed a computational approach to prioritize potential targets. A pathway/genome database (PGDB) integrates pathway information with information about the complete genome of an organism. We have constructed PlasmoCyc, a PGDB for Plasmodium falciparum 3D7, using its annotated genomic sequence. In addition to the annotations provided in the genome database, we add 956 additional annotations to proteins annotated as “hypothetical” using the GeneQuiz annotation system. We apply a novel computational algorithm to PlasmoCyc to identify 216 “chokepoint enzymes.” All three clinically validated drug targets are chokepoint enzymes. A total of 87.5% of proposed drug targets with biological evidence in the literature are chokepoint reactions. Therefore, identifying chokepoint enzymes represents one systematic way to identify potential metabolic drug targets.

References

43